Home
Clinical Condition
Meningitis
Respiratory
Endocarditis
Intra-abdominal
Urinary Tract Infection
Skin and Soft tissue
Skeletal (Bone & Joints)
Bacteremia and Undifferentiated
Microbiology
Gram positive cocci
Gram negative bacilli
Antibiotics
Penicillin
Ampicillin
Oxacillin
Cefazolin
Cefuroxime
Ceftriaxone
Ceftazidime
Imipenem
Meropenem
Piperacillin-Tazobactam
Ticarcillin-Clavulanic acid
Trimethroprim/Sulfamethoxazole
Ciprofloxacin
Levofloxacin
Gentamicin
High Level Gentamicin
High Level Streptomycin
Tobramycin
Tetracycline
Erythromycin
Clindamycin
Nitrofurantoin
Location
Febrile Neutropenia
Febrile Neutropenia
Bottom Line
Defined as:
Absolute neutrophil count (ANC) of
≤
0.5 x10
9
/L
or
≤
1 x 10
9
/L
with an anticipated decline to less than
≤
0.5 x10
9
/L
within a 48-hour period
PLUS
Single oral temperature of
≥
38.3 ËšC
or a sustained temperature of
≥
38.0ËšC
over one hour
High-risk patients are those with
Anticipated duration of neutropenia of ≥ 7 days
AND
Profound neutropenia – ANC
≤ 0.1 x10
9
/L
ANC count is the neutrophil count, NOT the total white count (WBC)
Blood cultures must be drawn peripherally and from any central venous catheter (CVC)
Empiric coverage for those with indwelling CVCs can include vancomycin, if signs or symptoms suggest a line-associated infection
Empiric Treatment must include antipseudomonal coverage
Empiric Therapy
Without CVC
Ceftazidime
2g IV q8h or
Piperacillin /Tazobactam
4.5g IV q6h (adjust for renal dysfunction if present)
With CVC and signs or symptoms suggesting a line-associated infection
Any of the above PLUS Vancomycin at 15mg/kg IV q12h (adjust for renal dysfunction if present)
Share by: